title: Effect of type of dialysis membrane on bone in haemodialysis patients.
abstract: BACKGROUND
  Uraemic bone disease is the result of a number of factors modulating bone formation and resorption in a complex manner. In the present study, the hypothesis tested was that the type of haemodialysis membrane used for renal replacement therapy might also play a role.
  
  
  METHODS
  We conducted a prospective, open study in 24 chronic haemodialysis patients who were randomized to dialysis treatment with either cellulosic (CELL group, n=11) or polyacrylonitrile (AN-69 group, n=13) membrane for 9 months. Repeated determinations of plasma parameters reflecting bone turnover were done in all patients, and a bone biopsy in a subgroup at the start and end of study.
  
  
  RESULTS
  At the start, mean plasma intact parathyroid hormone levels were comparable between the two groups and they did not vary significantly at 9 months of treatment. Similarly, plasma bone-specific alkaline phosphatase and osteocalcin (markers of bone formation), and cross-laps (marker of bone resorption) remained unchanged. However, plasma insulin-like growth factor-I (IGF-I) progressively decreased from 169 to 119 ng/ml in AN-69 group (P<0.01), whereas it remained unchanged in CELL group. In addition, the levels of IGF binding protein (IGFBP)-1 and IGFBP-2 were increased while the levels of IGFBP-5 were decreased in AN-69 group. In the five patients of each group who had repeat bone biopsies, histomorphometric analysis showed a decrease in osteoblast surface, osteoclast surface and osteoclast number in AN-69 group at 9 months, compared with baseline values measured at the start of the study. In contrast, all three parameters significantly increased in the CELL group at 9 months (P<0.001 for the difference between each of the three parameters). Bone formation rate decreased by 31% in the AN-69 group, but increased by 50% in CELL group. However, this latter difference was not statistically significant. Plasma interleukin (IL)-6 and soluble IL-6 receptor levels did not change in the two groups of patients who had undergone bone biopsy.
  
  
  CONCLUSIONS
  Dialysis with CELL membrane was associated with increased bone turnover whereas the use of AN-69 membrane was associated with decreased bone turnover, suggesting a beneficial effect of the latter on high-turnover uraemic bone disease. However, as the number of patients with repeat bone biopsies was small, these findings need to be confirmed in a larger study. Further studies are also needed to evaluate whether or not the changes in IGF system components play a role in decreased bone cell activity in patients on dialysis using the AN-69 polyacrylonitrile membrane.
authors.affiliation: Hospital Curry Cabral, Lisbon, Portugal.
authors.forename: A
authors.initials: A
authors.lastname: Ferreira
authors.forename: A
authors.initials: A
authors.lastname: Ghazali
authors.forename: J
authors.initials: J
authors.lastname: Galvão
authors.forename: J C
authors.initials: JC
authors.lastname: Souberbielle
authors.forename: P M
authors.initials: PM
authors.lastname: Jehle
authors.forename: S
authors.initials: S
authors.lastname: Mohan
authors.forename: B
authors.initials: B
authors.lastname: Descamps-Latscha
authors.forename: R
authors.initials: R
authors.lastname: Oprisiu
authors.forename: A
authors.initials: A
authors.lastname: Fournier
authors.forename: T B
authors.initials: TB
authors.lastname: Drüeke
mesh_terms: D000180:Acrylic Resins; D000181:Acrylonitrile / Q000031:analogs & derivatives*; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001672:Biocompatible Materials; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D001842:Bone and Bones / Q000378:metabolism* / Q000473:pathology; D002118:Calcium / Q000097:blood; D002482:Cellulose; D005602:France; D006801:Humans; D006961:Hyperparathyroidism / Q000209:etiology; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D015850:Interleukin-6 / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood / Q000503:physiopathology* / Q000628:therapy*; D008567:Membranes, Artificial; D015675:Osteocalcin / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D019947:Receptors, Interleukin-6 / Q000097:blood; D006435:Renal Dialysis / Q000295:instrumentation*; D013030:Spain; D044465:White People
chemical_list: D000180:Acrylic Resins; D001672:Biocompatible Materials; D015415:Biomarkers; D018969:Insulin-Like Growth Factor Binding Proteins; D015850:Interleukin-6; D008567:Membranes, Artificial; D010281:Parathyroid Hormone; D019947:Receptors, Interleukin-6; D015675:Osteocalcin; D010758:Phosphorus; C016892:AN-69; D007334:Insulin-Like Growth Factor I; D002482:Cellulose; D000469:Alkaline Phosphatase; D000181:Acrylonitrile; D002118:Calcium